SuperworthNexentis Technologies NXTS
- Market cap
- $761.8K
- PE
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Forward PE
- n/m
- not a meaningful number
- Price to sales
- n/m
- one or more of the four quarters through 2026-06-30 missing
- EV/EBIT
- n/m
- a loss over the last year
- Revenue, 12 months
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Net margin
- n/m
- one or more of the four quarters through 2026-06-30 missing
- Free cash flow yield
- n/m
- not a meaningful number
Charts
Financials
| Income statement | Q3 FY23 | Q4 FY23 | Q1 FY24 | Q2 FY24 | Q3 FY24 | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $0 | n/a | $43.8K−64% | $16.5K−55% | $9.1K | n/a | $66K+51% | $0 | $2K−78% | n/a | n/a | n/a | |
| Cost of revenue | $476−98% | n/a | $28K−35% | $5.8K−79% | $76.8K+16026% | n/a | $14K−50% | $2K−65% | $2K−97% | n/a | n/a | n/a |
| Gross profit | −$476 | n/a | $15.9K−80% | $10.8K+12% | −$67.7K+14114% | n/a | $52K+228% | −$2K | $0 | n/a | n/a | n/a |
| R&D | $1.7M+753% | n/a | $115.9K−3% | $6K−64% | $19K−99% | n/a | $20K−83% | $9K+50% | $52K+174% | $98K | $275K+1275% | $373K+4044% |
| SG&A | $1.2M−27% | n/a | $799.1K−53% | $852K+2% | $1.3M+16% | $298K | $503K−37% | $2.6M+208% | $1.3M−6% | $362K+22% | $1.9M+278% | $1.3M−52% |
| −$2.9M+62% | n/a | −$899.1K−48% | −$847K+1% | −$1.4M−50% | −$219K | −$503K−44% | −$2.6M+210% | −$1.3M−8% | $549K | −$8.2M+1535% | −$1.9M−29% | |
| Pre-tax income | n/a | n/a | n/a | n/a | n/a | n/a | −$1.1M | −$4.4M | n/a | n/a | −$7.4M+567% | −$11.2M+155% |
| n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | −$23K | −$23K | |
| Net income | −$2.4M+35% | −$1.7M+24% | −$769K−55% | −$787.4K+11% | −$2.3M−4% | −$1.4M−21% | −$1.2M+55% | −$4.5M+473% | $429K | $1.3M | −$6.6M+452% | −$11.1M+147% |
| −$436.10−44% | −$245.00−51% | −$63.70−89% | −$56.35−67% | −$95.55−78% | −$29.40−88% | −$85.25+34% | −$44.26−22% | $6.79 | n/a | −$10.74−87% | −$13.66−69% | |
| 5.4K+139% | 7.1K+154% | 12.1K+325% | 13.9K+232% | 23.8K+337% | 45.5K+542% | 102K+744% | 101.9K+632% | 138.2K+482% | n/a | 612.7K+501% | 816.1K+701% |
EPS, diluted: 6 periods, Q4 FY19 to Q4 FY24: quarter's net income to common over its shares, to the cent.
Diluted shares: Q4 FY19: a loss quarter: its basic count, share-days: the 12-month average over 365 days less the 9-month over 273, the two on one basis (x7). 5 periods, Q4 FY20 to Q4 FY24: a loss quarter: its basic count, share-days: the 12-month average less the 9-month, weighted by days.
From each company's 10-Q and 10-K filings, the newest version of each figure. Quarters are as filed (a fourth quarter is the year less its first nine months), fiscal years as the 10-K prints them, restated where a later 10-K restated them, and balance sheet lines as of the period's end. A quarter whose 10-Q isn't filed yet is from the company's results release. Growth is on the same period a year earlier. A dash is a period with no figure for the line: the filing doesn't print it, or it hasn't been read yet.
Peers
Companies in Drug Manufacturers - General nearest Nexentis Technologies' size, closest first.
| Company | Market cap | PE | Its 10y median PE | Fwd PE | P/S | Revenue growth | Net margin |
|---|---|---|---|---|---|---|---|
| NXTSNexentis Technologies | $761.8K | n/m | n/a | n/m | n/m | n/m | |
| LABTLakewood-Amedex Biotherapeutics | $734.6K | n/m | n/a | n/m | n/m | n/m | |
| JAGXJaguar Health | $702.9K | n/m | n/a | 0.0× | +136% | n/m | |
| VBIOValion Bio | $834.3K | n/m | n/a | n/m | n/m | n/m | |
| DCOYDecoy Therapeutics | $635.5K | n/m | n/a | n/m | n/m | n/m | |
| SBFMSunshine Biopharma | $581.6K | n/m | n/a | 0.0× | −3% | −16.5% | |
| ARTLArtelo Biosciences | $1.3M | n/m | n/a | n/m | n/m | n/m | |
| LNAILunai Bioworks | $1.5M | n/m | n/a | n/m | n/m | n/m | |
| GNPXGenprex | $1.5M | n/m | n/a | n/m | n/m | n/m | |
| GOVXGeoVax Labs | $1.5M | n/m | n/a | n/a | −100% | n/a | |
| ONCOOnconetix | $1.7M | n/m | n/a | n/m | n/m | n/m | |
| Peer median | $1.1M | n/a | n/a | 0.0× | −3% | −16.5% |
More on Nexentis Technologies
Each number over time
Its groups
About
- Industry
- Drug Manufacturers - General
- Sector
- Healthcare
Valuation data, not investment advice. Prices as of .